Compare · MTD vs TXG
MTD vs TXG
Side-by-side comparison of Mettler-Toledo International Inc. (MTD) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MTD and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- MTD is the larger of the two at $26.47B, about 4.8x TXG ($5.55B).
- Both names hit the wire about 2 times in the past 4 weeks.
- TXG has more recent analyst coverage (25 ratings vs 23 for MTD).
- Company
- Mettler-Toledo International Inc.
- 10x Genomics Inc.
- Price
- -
- -
- Market cap
- $26.47B
- $5.55B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1997
- 2019
- News (4w)
- 2
- 2
- Recent ratings
- 23
- 25
Mettler-Toledo International Inc.
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest MTD
- Mettler-Toledo International Inc. to Host Second Quarter 2026 Earnings Conference Call
- SEC Form 11-K filed by Mettler-Toledo International Inc.
- Wolfe Research resumed coverage on Mettler-Toledo
- SEC Form SD filed by Mettler-Toledo International Inc.
- Head of Asia & Pacific Wong Ann Ping Richard was granted 103 shares, increasing direct ownership by 19% to 645 units (SEC Form 4)
- Head of PI, Retail, and GSC Wittorf Oliver was granted 87 shares, increasing direct ownership by 21% to 495 units (SEC Form 4)
- Chief Financial Officer Vadala Shawn was granted 291 shares, increasing direct ownership by 6% to 5,579 units (SEC Form 4)
- Head of Process Analytics Keller Gerry was granted 100 shares, increasing direct ownership by 63% to 259 units (SEC Form 4)
- President and CEO Kaltenbach Patrick was granted 810 shares, increasing direct ownership by 22% to 4,480 units (SEC Form 4)
- Chief Human Resources Officer Graham-Bryce Susan was granted 71 shares, increasing direct ownership by 16% to 517 units (SEC Form 4)
Latest TXG
- 10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
- Chief Executive Officer Saxonov Serge sold $1,033,269 worth of shares (30,000 units at $34.44) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,108,380 units (SEC Form 4)
- IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist
- Director Suliman Shehnaaz sold $186,756 worth of shares (5,723 units at $32.63) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 31,722 units (SEC Form 4)
- 10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
- SEC Form 144 filed by 10x Genomics Inc.
- 10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
- Director Teichmann Sarah A. was granted 8,829 shares, increasing direct ownership by 33% to 35,609 units (SEC Form 4)
- Director Suliman Shehnaaz was granted 8,829 shares, increasing direct ownership by 31% to 37,445 units (SEC Form 4)
- Director Stuelpnagel John R was granted 8,829 shares, increasing direct ownership by 2% to 368,436 units (SEC Form 4)